UK Keeps Palantir on NHS Data Platform Until 2029
Ministers will not use a 2027 break clause on Palantir's £330M NHS data deal, extending it to 2029 while a replacement is bought.
The British government will keep US software company Palantir on a major NHS data contract in England until 2029, rather than using an early exit clause that would have allowed it to end the deal in 2027, according to the BBC, the Guardian and other outlets. The contract, worth up to £330 million, was originally due to run until 2031.
Palantir, a data-analytics company co-founded by investor Peter Thiel, leads a group of suppliers running the NHS Federated Data Platform, software that links data held by hospitals and other healthcare providers. NHS England awarded the contract in 2023.
What happened
Health minister James Frith told MPs on Monday that the platform will stay on its current contract until March 2029 while the government buys a replacement, as reported by The Register. The Guardian reported that Frith said ending Palantir’s role in 2029 is meant to strengthen public trust, reduce dependence on a single supplier and allow UK companies to provide digital infrastructure.
The Department of Health and Social Care chose a roughly two-year extension over triggering a break clause, which would have allowed an exit as early as spring 2027. The Financial Times reported that an internal review concluded using the clause was not practical. Frith said exit provisions existed but pointed to the platform’s performance and the time a replacement would need.
The formal procurement for the next version of the platform is not expected to begin until the second half of 2027 and to take about 18 months, according to The Register. Frith said the tender would welcome UK small and medium-sized firms as well as international providers.
Reaction
The decision drew criticism from some Labour MPs. Chi Onwurah, who chairs the House of Commons science and technology committee, called it “deeply disappointing”, the Guardian reported. The Register quoted her as saying: “If a break clause cannot be exercised because of continuity of care, it is not a break clause; it is a lock-in.”
Martin Wrigley, a Liberal Democrat MP, said ministers had “kicked the can down the road”, according to the Guardian. Ben Coleman, a Labour member of the health committee, welcomed the end of reliance on one supplier but said it must not disrupt patient care.
Campaign group Foxglove, which has opposed the contract since 2023, said the extension lets Palantir “embed itself even more deeply in public services” and strengthens its position in the next procurement. Amnesty International, which had urged the government to use the break clause, welcomed the 2029 end date as a win for campaigners and healthcare workers, the Guardian reported.
Tom Watson, a former Labour deputy leader who now works with Palantir, called the extension the right decision and said the programme is “significantly exceeding its benefits forecast”, according to coverage of the announcement. The articles reviewed did not include a direct statement from Palantir, and the company has not said publicly whether it will bid for the replacement contract. The Guardian noted that the company insists its product delivers the claimed benefits, which some doctors and hospital managers doubt.
Why it matters
The platform has been politically contentious since its award. Critics have raised concerns about patient data, the company’s work with US immigration authorities and its ties to US politics, while supporters point to efficiency gains in hospitals. The Guardian reported that many NHS trusts have declined to use the system, and that NHS England removed a website claim that 137 trusts were benefiting after the newspaper reported that 29 were using it never or rarely.
What comes next
The government is expected to launch the tender for a successor platform in 2027. It is not yet known whether Palantir will bid, or how the new contract will be structured. Reports differ slightly on the original end date, with some citing 2031, and the exact terms of the contract remain partly redacted.


